Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kowa Research Institute, Inc.
• Treatments: Cilostazol

Criteria

Inclusion Criteria:

• Stable claudication symptoms

Exclusion Criteria:

• Lower extremity amputation

• Signs or symptoms of critical leg ischemia (CLI)

• Uncontrolled hypertension

• Tachycardia

• Poorly controlled diabetes

• Hypercholesterolemia